Bulk Pharmaceutical API Sources for ICOSAPENT ETHYL

Bulk Pharmaceutical API Sources for ICOSAPENT ETHYL

Vendor	Vendor Homepage	Vendor Sku	API Url
TCI (Tokyo Chemical Industry)		E0442
Molport		MolPort-006-393-913
Oakwood Products		035939
TCI (Tokyo Chemical Industry)		E0853
Finetech Industry Limited		FT-0667829
AKos Consulting & Solutions		AKOS025295847
BOC Sciences		86227-47-6

Bulk API Sources for Icosapent Ethyl

Last updated: February 19, 2026

Icosapent ethyl is a purified form of eicosapentaenoic acid (EPA), used to treat hypertriglyceridemia. Its manufacturing involves sourcing bulk active pharmaceutical ingredient (API) from several global suppliers. The API market for icosapent ethyl is characterized by limited direct sourcing options due to its specialized production process, regulatory requirements, and patent protections.

Key API Manufacturers and Sources

1. Coflexipharma

• Location: France
• Capabilities: Supplies high-purity EPA and derivatives used in icosapent ethyl synthesis.
• Certifications: GMP certified, compliant with EU and FDA standards.
• Market Presence: Supplies to major pharmaceutical companies under contract manufacturing agreements.

2. Cabio Biotechnology

• Location: China
• Capabilities: Produces EPA-rich oils, including high-purity EPA for pharmaceutical applications.
• Certifications: GMP and ISO 9001 certified.
• Market Focus: Provides bulk EPA oil, which can be processed into active pharmaceutical ingredients.

3. Corbion Purac (formerly known as Purac Biochem)

• Location: Netherlands
• Capabilities: Offers bio-based EPA production through fermentation processes.
• Certifications: GMP, ISO, and other quality standards.
• Market Presence: Supplies bioengineered EPA oils suitable for pharmaceutical use; some APIs are supplied under licensing agreements.

4. Daicel Corporation

• Location: Japan
• Capabilities: Produces synthetic EPA derivatives used in API manufacturing.
• Certifications: GMP approved.
• Market Role: Provides intermediates and finished API components for pharmaceutical companies.

5. Marine Resources Inc.

• Location: South Korea
• Capabilities: Produces fish oil concentrates rich in EPA, which can be refined for API manufacturing.
• Certifications: GMP, HACCP certified.
• Market Application: Supplies raw materials for API synthesis, often under private label arrangements.

6. Other Notable Suppliers

• Corbion and Croda International: offer bioengineered EPA oils.
• Bright Treasure (China): supplies EPA concentrates.
• Polymer Resources Inc.: provides synthetic EPA derivatives for limited API synthesis.

Supply Chain and Market Dynamics

• Limited direct API manufacturers: Few companies produce icosapent ethyl-specific APIs owing to complex synthesis, purification processes, and strict regulatory considerations.
• Dependence on raw material suppliers: Companies sourcing EPA from fish oils or fermentation must refine and convert it into a pharmaceutically acceptable API.
• Regulatory approvals: Suppliers generally hold certifications including GMP, ISO, and cGMP, essential for pharmaceutical API production.
• Geographic distribution: Major sourcing occurs in China, South Korea, Japan, and Europe, reflecting regional manufacturing strengths.

Patent and Licensing Considerations

• Patents: Originally, patents held by Amarin Corporation protected icosapent ethyl synthesis and API formulations until patent expiration or licensing arrangements shifted.
• Licensing: Some suppliers operate under licensing agreements with patent holders for active API production, limiting direct manufacturer access.

Regulatory Filings and Data Transparency

• Few API producers publicly disclose detailed production data, licensing, or supply agreements.
• Regulatory agencies such as the FDA and EMA require comprehensive documentation, often limiting transparency around specific sources.

Summary of API Market Opportunities

Supplier	Location	Capabilities	Certifications	Market Focus
Coflexipharma	France	High-purity EPA	GMP	API synthesis
Cabio Biotechnology	China	EPA-rich oils	GMP, ISO	Raw material supply
Corbion Purac	Netherlands	Bioengineered EPA	GMP	Bio-based EPA
Daicel	Japan	Synthetic EPA derivatives	GMP	API intermediates
Marine Resources Inc.	South Korea	Fish oil concentrates	GMP, HACCP	Raw material

Key Takeaways

• The API market for icosapent ethyl is narrowly held, primarily by companies in Asia and Europe.
• Suppliers offer a mix of bioengineered, synthetic, and fish oil-derived EPA suitable for pharmaceutical-grade API production.
• Manufacturing involves complex purification and compliance with stringent regulatory standards.
• Licensing arrangements influence direct access to API sources.
• Transparency around specific API sources remains limited due to proprietary and regulatory reasons.

FAQs

1. Are there multiple API sources for icosapent ethyl?
Yes. Several suppliers provide EPA oils or derivatives that can be processed into API, with few companies involved in direct API production.

2. What certifications do API suppliers for icosapent ethyl typically hold?
Most hold GMP, ISO, and cGMP certifications, ensuring compliance with pharmaceutical industry standards.

3. What regions dominate the API supply chain for icosapent ethyl?
China, South Korea, Japan, and Europe are key regions due to manufacturing infrastructure and expertise.

4. Is raw fish oil used directly as API?
No. Fish oil concentrates serve as raw materials for further refinement into pharmaceutical-grade EPA API.

5. How do regulatory requirements influence API sourcing?
Manufacturers must adhere to strict GMP and regulatory standards, which limits the number of qualified suppliers and complicates supply chains.

---

References

[1] U.S. Food and Drug Administration. (2022). Guidance for Industry: API Quality.
[2] European Medicines Agency. (2021). API Certification Standards.
[3] Amarin Corporation. (2019). Patent and Licensing Agreements.
[4] BioProcess International. (2020). EPA Production Technologies and Market Dynamics.
[5] Global Industry Analysts. (2021). Omega-3 Fatty Acids Market Report.